The Evolution of Obesity Care: What Have We Learned in the GLP-1 Era?
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
The Evolution of Obesity Care: What Have We Learned in the GLP-1 Era?
-
ナレーター：
-
著者：
In this episode of The Pulse in 15, Mary reconnects with Dr. Sean Hashmi, a leader in Lifestyle and Obesity Medicine at Kaiser Permanente, to explore how obesity treatment has evolved since their first discussion in 2022. At that time, GLP-1 medications were just beginning to gain attention. Today, they have transformed conversations around obesity management, healthcare costs, long-term outcomes, and employer health plan strategy. Dr. Hashmi shares what real-world experience has taught us about sustainable success, long-term use, and medication discontinuation, while providing practical insights for employers evaluating obesity care programs.
Key Takeaways
- Understand how obesity treatment has evolved since GLP-1 medications entered mainstream clinical practice.
- Explore what providers are seeing regarding long-term outcomes, sustainability, and measures of success beyond weight loss.
- Gain insight into whether patients can successfully transition off GLP-1 medications and maintain their results.
- Identify the key elements employers should consider when developing an obesity management strategy that extends beyond medication coverage alone.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません